Menarini launches Balzak Pplus ® for the treatment of hypertension blood.
Badalona, 2011-July the new antihypertensive Menarini group, Balzak Pplus ®, is a triple combination fixed dose of an ARA II (olmesartan medoxomilo), a calcioantagonista (maleate) and a diuretic (hydrochlorothiazide). Is indicated as replacement therapy in hypertensive adult patients as replacement therapy in casoscuya whose blood pressure estéá properly controlled adequately with the combination of olmesartan medoxomilo, maleate and hydrochlorothiazide, taken as a combination double (including olmesartan medoxomilo) along with a formulation of a single componente.con olmesartan medoxomilo with another combination of the components or taken both separately.
in a randomized, controlled, double blind study included 2,492 patients with hypertension of moderate gravesevera, lala triple combination provided a further reduction in both systolic and diastolic blood pressure as well as a greater patients númeroporcentaje than respondedoresalcanzaron the objectives of blood pressure with dual therapy even those sub-groups of patients of difficult to control: over 65s, diabetic, black and with metabolic syndrome. EAsimismo, the treatment offers better coverage for 24 hours by a single daily tomatoma that the respective dual therapies and in turn has been well tolerated in the different studies. Available in five different presentations to adapt to the needs of each paciente.fue generally tolerated, even in those difficult to control patient subgroups: the over 65s, diabetic, black and with syndrome metabolic
in Spain is currently estimated that only 40 percent of hypertensive patients are controlled, therapeutic failure to the patient to be one of the main causes of this under control. This is due, to a greater extent, to a third of the mismospacientes require three or more drugs to control hypertension sula, is therefore expected that useful combination to fixed-dose triple unala resultea…
, European guidelines of hypertension recommended the combination of an inhibitor of the Renin angiotensin ARA II system, a calcioantagonista and a loop diuretic such as combination of three drugs when necessary as well as the combinations to dose establishes sussus mechanisms of action are complementary and allow mejorarn effectiveness, the tolerability of treatment and compliance by the patient.
cardiovascular diseases are the leading cause of death in Spain and high blood pressure is the main factorfactor of cardiovascular risk and the most common in our country, with a prevalence of over 40 per cent in patients over the age of 35 years and 68 percent in people over 60. In addition, in the majority of hypertensive patients often padecercoexistir also as dyslipemias or diabetes, diseases that contribute to increasing the total cardiovascular risk of these pacientes.lo that converts to high blood pressure in a high risk factor cardiovascular.
research Menarini.
Menarini Group devoted much of his effort to innovation and the search for pharmaceutical products that meet the needs of society. In this regard, the Group has six r & d centres in Europe: four in Italy (Florence, Pomezia, Milan and Pisa), one in Germany (Berlin) and one in Spain (Badalona). Menarini in Spain Centre has as a priority line of research development of medication to fight the pain, inflammation and asthma, cardiovascular disease, disorders of gastrointestinal motility and viral skin infections.
Menarini is an international pharmaceutical group with 125 years of history that is present in more than 100 countries in Europe, Asia, Africa and America. In Spain, he started his career for 50 years and today employs 550 people in our country.
